Skip to main content

Advertisement

SpringerLink
Log in

Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer—Population-Based Analysis with Propensity Score Matching

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

This population-based study evaluated the survival impact of postoperative radiotherapy (PORT) in left-sided pancreatic cancer. The Surveillance, Epidemiology, and End Results (SEER) database was used to identify patients with surgically resected left-sided pancreatic adenocarcinoma from 2004 to 2010. Propensity score matching was conducted to compare PORT and non-PORT groups. A total of 445 patients were identified, and PORT was performed in 180 (40 %) patients. In the unmatched population, there were no significant differences in overall survival (OS) (P = 0.197) and cause-specific survival (CSS) (P = 0.379) between the PORT and non-PORT groups. After propensity score matching, the patients treated with PORT had longer median OS (P = 0.012) and CSS (P = 0.039) than the non-PORT group. In propensity-adjusted multivariate analysis, non-receipt of PORT was a poor prognostic factor in OS (hazard ratio [HR] 1.39, 95 % confidence interval [CI] 1.08–1.79), and CSS (HR 1.31, 95 % CI 1.01–1.71). The log odds of positive lymph nodes (LOODS) (≥−0.73) was also associated with worse OS (P = 0.003) and CSS (P = 0.001). In left-sided pancreatic cancer, considering the addition of PORT is a reasonable option as in pancreatic head cancer. The LOODS was suggested as a strong predictive indicator of the patients’ prognoses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.

    Article  PubMed  Google Scholar 

  2. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118-28.

    Article  PubMed  Google Scholar 

  3. Hazard L, Tward JD, Szabo A, Shrieve DC. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer 2007;110:2191-201.

    Article  PubMed  Google Scholar 

  4. Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005;9:922-7.

    Article  PubMed  Google Scholar 

  5. Redmond KJ, Wolfgang CL, Sugar EA, Ahn J, Nathan H, Laheru D, Edil BH, Choti MA, Pawlik TM, Hruban RH, Cameron JL, Herman JM. Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Ann Surg Oncol 2010;17:3112-9.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Merchant NB, Rymer J, Koehler EA, Ayers GD, Castellanos J, Kooby DA, Weber SH, Cho CS, Schmidt CM, Nakeeb A, Matos JM, Scoggins CR, Martin RC, Kim HJ, Ahmad SA, Chu CK, McClaine R, Bednarski BK, Staley CA, Sharp K, Parikh AA. Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg 2009;208:829-38; discussion 38-41.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Mattiucci GC, Ippolito E, D’Agostino GR, Alfieri S, Antinori A, Crucitti A, Balducci M, Deodato F, Luzi S, Macchia G, Smaniotto D, Morganti AG, Valentini V. Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Ann Surg Oncol 2013;20:423-9.

    Article  PubMed  Google Scholar 

  8. Czito BG, Willett CG. Adjuvant radiation therapy for distal pancreatic cancer: is there a role? Ann Surg Oncol 2010;17:3082-4.

    Article  PubMed  Google Scholar 

  9. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981-90.

    Article  PubMed Central  PubMed  Google Scholar 

  11. McDade TP, Hill JS, Simons JP, Piperdi B, Ng SC, Zhou Z, Kadish SP, Fitzgerald TJ, Tseng JF. A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma. Cancer 2010;116:3257-66.

    Article  PubMed  Google Scholar 

  12. Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer 2014;120:1171-7.

    Article  PubMed  Google Scholar 

  13. Sugawara A, Kunieda E. Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score surveillance, epidemiology, and end results database analysis. J Surg Oncol 2014;110:960-6.

    Article  PubMed  Google Scholar 

  14. Bergenfeldt M, Moesgaard F, Burcharth F. Curative resection for left-sided pancreatic malignancy. HPB (Oxford) 2006;8:211-5.

    Article  Google Scholar 

  15. Yamamoto J, Saiura A, Koga R, Seki M, Katori M, Kato Y, Sakamoto Y, Kokudo N, Yamaguchi T. Improved survival of left-sided pancreas cancer after surgery. Jpn J Clin Oncol 2010;40:530-6.

    Article  PubMed  Google Scholar 

  16. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.

    Article  Google Scholar 

  17. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-8.

    Google Scholar 

  18. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 2011;46:399-424.

    Article  Google Scholar 

  19. Ling Q, Xu X, Zheng SS, Kalthoff H. The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. Hepatobiliary Pancreat Dis Int 2013;12:480-7.

    Article  PubMed  Google Scholar 

  20. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.

    Article  CAS  PubMed  Google Scholar 

  21. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.

    Article  CAS  PubMed  Google Scholar 

  22. Kim BH, Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Joo I, Ha SW. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Cancer Res Treat 2015;47:274-81.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, Dubois JB, Fastner G, Herman JM, Maidment BW, 3rd, Miller RC, Regine WF, Reni M, Sharma NK, Ippolito E, Valentini V. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys 2014;90:911-7.

    Article  PubMed  Google Scholar 

  24. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, Choti MA, Pawlik TM. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008;15:165-74.

    Article  PubMed  Google Scholar 

  26. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13:1337-44.

    Article  PubMed  Google Scholar 

  27. La Torre M, Cavallini M, Ramacciato G, Cosenza G, Rossi Del Monte S, Nigri G, Ferri M, Mercantini P, Ziparo V. Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis. J Surg Oncol 2011;104:629-33.

    Article  PubMed  Google Scholar 

  28. Ashfaq A, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J Gastrointest Surg 2014;18:1929-35.

    Article  PubMed  Google Scholar 

  29. Sun Z, Xu Y, Li de M, Wang ZN, Zhu GL, Huang BJ, Li K, Xu HM. Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection. Cancer 2010;116:2571-80.

  30. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003;43:121-37.

    Article  Google Scholar 

  31. La Torre M, Nigri G, Petrucciani N, Cavallini M, Aurello P, Cosenza G, Balducci G, Ziparo V, Ramacciato G. Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes. Pancreatology 2014;14:289-94.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea

    Yu Jin Lim, Kyubo Kim, Eui Kyu Chie, BoKyong Kim & Sung W. Ha

  2. Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea

    Eui Kyu Chie & Sung W. Ha

Authors
  1. Yu Jin Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyubo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eui Kyu Chie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. BoKyong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sung W. Ha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyubo Kim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lim, Y.J., Kim, K., Chie, E.K. et al. Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer—Population-Based Analysis with Propensity Score Matching. J Gastrointest Surg 19, 2183–2191 (2015). https://doi.org/10.1007/s11605-015-2941-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-015-2941-x

Keywords

Search

Navigation